<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732939</url>
  </required_header>
  <id_info>
    <org_study_id>307BCNeo-01</org_study_id>
    <nct_id>NCT01732939</nct_id>
  </id_info>
  <brief_title>Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Affiliated to Military Medical Science, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Affiliated to Military Medical Science, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for
      invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines plus
      taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hope to get preliminary results for the breast cancer patients who are
      given different neoadjuvant chemothetapy regimens. The patients are randomized two
      chemotherapy regimens. One is anthracyclines plus taxanes for 6-8 cycles,the other is
      anthracyclines plus taxanes for 3-4 cycles ,then switch tovinorelbine plus cisplatinum for
      3-4 cycles.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response rate, safety</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AT</arm_group_label>
    <description>Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-NP</arm_group_label>
    <description>docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        diaganosis of invasive breast cancer, tumor size &gt; 2.0cm by MRI or ultrasound or clinical
        examination.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of invasive ductal or lobular breast cancer.

          -  Previously untreated (no chemotherapy or hormonal therapy or radiation therapy)
             invasive breast cancer.

          -  no anti-Her2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive)

          -  Performance Status ECOG &lt;2

          -  Age &gt; 18 years

          -  Tumor &gt; 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky
             &gt;50%

          -  Lab test :

               -  Absolute neutrophil count &gt; 1,500/mm3

                    -  Total Bilirubin ≤ 2×ULN

                    -  AST and ALT ≤ 2.5×ULN

               -  serum creatinine ≤ 1.5×ULN

        Exclusion Criteria:

          -  Pregnant or breast feeding patients are excluded

          -  stage Ⅳ breast cancer

          -  History of non-breast malignancies within the 5 years prior to study entry, except for
             the following: carcinoma in situ of the cervix, carcinoma in situ of the
             colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin

          -  uncontrolled cardiac disease

          -  Active infection or chronic infection requiring chronic suppressive antibiotics

          -  History of hypersensitivity reaction to investigating drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zefei Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Affiliated Military Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital affiliated academy military medical science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Wang, MD</last_name>
      <phone>8610-66947430</phone>
    </contact>
    <contact_backup>
      <last_name>Shaohua ZHANG, MD</last_name>
      <phone>8610-66947173</phone>
    </contact_backup>
    <investigator>
      <last_name>Zefei Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2012</study_first_submitted>
  <study_first_submitted_qc>November 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2012</study_first_posted>
  <last_update_submitted>February 17, 2014</last_update_submitted>
  <last_update_submitted_qc>February 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

